|
 Global stocks took a beating on Thursday as a fresh row between Washington and Beijing over U.S. legislation on Hong Kong threatened to undermine their trade talks and delay a "phase one" deal that investors had initially hoped to be signed by now.
|
RELATED ARTICLES | | |
|
Questions of Prince Andrew's billionaire lifestyle arise amid his public retreat New York Post Prince Andrew Makes Shocking Move to Quit Royal Duties After Explosive Jeffrey Epstein Interview PEOPLE.comPrince under pressure: Is this the end for Andrew? Sky NewsPrince Andrew Opens the Door to a Slimmed-Down Monarchy Bloomberg
|
RELATED ARTICLES | | |
|
 More than 500 biotech companies operate in the US, doing their part to make it the world's hub for innovation. Only about 20 of them turn a profit, though, highlighting the dangers of the biotech sector. High overhead, long research terms, and the uncertainties of clinical testing and regulatory approval all weigh on them, making biotech at once the riskiest and most potentially profitable of the stock market's segments.Enter Joseph Edelman. The hedge fund veteran started Perceptive Advisors back in 1999 with just $6 million, and his hedge has grown to hold over $5 billion in assets under management today. Edelman's fund's flagship, the Perceptive Life Sciences Fund, specializes in small- and mid-cap biotech companies. That Edelman knows how to spot the winners is clear from the Life Sciences Fund's annualized gains of 30% since its inception.In the words of Brad Loncar, of Loncar Investments, biotech is the "most volatile sector in the stock market… More so than any industry, it's important to be diversified... Even excellent companies with great science fail all the time and have big setbacks, because it's that difficult of a business." Edelman has thrived in this difficult business for the last twenty years, and in his most recent 13F filing, for the quarter ending this past September 30, he doubled down on three companies.We've looked up each in the TipRanks database, to find a line on why.Amarin Corporation (AMRN)A mid-cap company, valued at $7 billion, Amarin is the largest
|
|
 (Bloomberg Opinion) -- "I think we have it under control."That's what Federal Reserve Chair Jerome Powell said when lawmakers in Washington asked him last week about the mid-September turmoil in short-term funding markets. New York Fed President John Williams said something similar on Tuesday. If Powell didn't sound entirely sure, it's for good reason — the Federal Open Market Committee apparently isn't, either. Minutes of the FOMC's October meeting released on Wednesday showed that officials are puzzled about how to best regain their handle on short-term interest rates. According to the minutes, policy makers were presented with two possible options: either frequent repo operations like the past two months, or establishing a standing fixed-rate facility.Fed officials hemmed and hawed:"Many participants noted that, once an ample supply of reserves is firmly established, there might be little need for a standing repo facility or for frequent repo operations. Some of these participants indicated that a basic principle in implementing an ample-reserves framework is to maintain reserves on an ongoing basis at levels that would obviate the need for open market operations to address pressures in funding markets in all but exceptional circumstances. Many participants remarked, however, that even in an environment with ample reserves, a standing facility could serve as a useful backstop to support control of the federal funds rate in the event of outsized shocks to the system.… A couple of other participants sugg
|
|
Private Label